Email this article Experience with ixel (milnaciprane hydrochloride) treatment of poststroke depression
- Authors: Gekht АВ1, Sorokina IB1, Bogolepova AN1, Gudkova AA1
-
Affiliations:
- Issue: Vol 78, No 10 (2003)
- Pages: 34-37
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29657
- ID: 29657
Cite item
Full Text
Abstract
Aim. To evaluate antidepressive efficacy ofixel in patients with poststroke depression (PSD).
Material and methods. The study included 59 PSD patients aged 43- 79 years divided into two
groups: the test group (31 patients) treated with antidepressive drugs and the control group (28 patients) was not treated with such drugs. The test group took a two-month treatment with oral ixel in a
dose 100 mg/day. The neurological status was assessed by Lindmark scale (LS), severity of depression - by Hamilton scale (HS).
Results. On ixel treatment day 10-14 the patients felt better, by the treatment day 60 depression disappeared in 60.9%, only borderline conditions were seen in 39.1%. Mean score by HS fell from 15.8
to 5.7. The controls showed moderate reduction of some symptoms of depression, mean score by HS
descreased insignificantly (from 14.5 to 13.4). By LS, significant differences between the groups were
not registered. Side effects arose in 10 patients, 6 of them withdrew.
Conclusion. Ixel is an effective drug against depression in stroke survivors.
Material and methods. The study included 59 PSD patients aged 43- 79 years divided into two
groups: the test group (31 patients) treated with antidepressive drugs and the control group (28 patients) was not treated with such drugs. The test group took a two-month treatment with oral ixel in a
dose 100 mg/day. The neurological status was assessed by Lindmark scale (LS), severity of depression - by Hamilton scale (HS).
Results. On ixel treatment day 10-14 the patients felt better, by the treatment day 60 depression disappeared in 60.9%, only borderline conditions were seen in 39.1%. Mean score by HS fell from 15.8
to 5.7. The controls showed moderate reduction of some symptoms of depression, mean score by HS
descreased insignificantly (from 14.5 to 13.4). By LS, significant differences between the groups were
not registered. Side effects arose in 10 patients, 6 of them withdrew.
Conclusion. Ixel is an effective drug against depression in stroke survivors.
References
- Гусев Е. И. Ишемическая болезнь головного мозга. М; 1992.
- Шмидт Е. В., Макинасий Т. А. Мозговой инсульт. Заболеваемость и смертность. Журн. невропатол. и психиатр. 1979; 4: 427-432.
- Гехт А. Б. Динамика клинических и нейрофизиологических показателей у больных ишемическим инсультом в раннем восстановительном периоде: Дис. д-ра мед. наук. М.; 1993.
- Боголепова А. Н. Высшие психические функции у больных в раннем восстановительном периоде ишемического инсульта. Дис. ... канд. мед. наук. М.; 1997.
- Labi M. L. С, Phillips Т. F., Gresham G. Е. Psychosocial disability in physically restored long-term stroke survivors. Arch. Phys. Med. Rehabil. 1980; 61: 561-565.
- Diamond P. Т., Holroyd S., Macciocchi S. N. et al. Prevalence of depression and outcome on the geriatric rehabilitation unit.Am. J. Phys. Med. Rehabil. 1995; 74 (3): 214-217
- . Andersen C, Vestergaard K., Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25 (6): 1099-1104.
- Morris P. L., Robinson R. G., Andrzejewski P. et al. Association of depression with 10-year poststroke mortality. Am. J. Psychiatry 1993; 150: 124-129.
- Neau J. P., [ngrand P., Mouille-Brachet С et al. Functional recovery and social outcome after cerebral infarction in young adults. Cerebrovasc. Dis. 1998; 8 (5): 296-302.
- Paolucci S., Antonucci G., Pratesi L. et al. Poststroke depression and its role in rehabilitation of inpatients. Arch. Phys. Med. Rehabil. 1999; 80: 985-990.
- Gustafson Y., Nilsson J., Mattsson M. et al. Epidemiology and treatment of post-stroke depression. Drugs Aging 1995; 7: 298-309.
- Kim J. S., Choi-Kwon S. Poststroke depression and emotional incontinence: correlation with lesion location. Neurology 2000; 54 (9): 1805-1810.
- Brola W., Szafraniec L. Depression as a complication ofstro Przegl. Lek. 1996; 53 (9): 690-692.
- Kotila M., Walfimo O. et al. The profile of recovery fn stroke and factors influencing outcome. Stroke 1984; 15 () 1039-1944.
- Schwartz J. A., Speed N. M., Brunberg J. A. et al. Depression stroke rehabilitation. Biol. Psychiatry 1993; 33 (10): 694-69
- Вейн А. М., Вознесенская Т. Г. Депрессии в неврологиской практике. М.;1998.
- Varga D. Neuropsychiatry complications after strol Ideggyog. Sz. 2002; 55 (3-4): 128-136.
- Mayo N. E., Wood-Dauphinee S., Cote R. et al. Activity, paticipation, and quality of life 6 months poststroke. Arch. Ph) Med. Rehabil. 2002; 83 (8): 1035-1042.
- Robinson R. G. Treatment issues in poststroke depression. D press Anxiety 1998; 8 (suppl. 1): 85-90.
- Whyte E., Mulsant B. Poststroke depression: epidemiolog pathophysiology, and biological treatment. Biol. Psychiati 2002; 52 (3): 253.
- Gainotti G., Antonucci G., Marra C., Paolucci S. Relation Ix tween depression after stroke, antidepressant therapy, an functional recovery. J. Neurol. Neurosurg. Psychiatry 2001;? (2): 258-261.
- Смулевич А. Б. Депрессии в общей медицине. М.; 2001.
- Тиганов А. С. Эндогенные депрессии: вопросы классификации и систематики. В кн.: Депрессии и коморбидны расстройства. М.; 1997. 12-26.
- Lecrubier У. Milnacipran: the clinical properties of SNRi. In Human Psychopharmacology.. 1997. 127-134.
- Cindmark В., Hamrin E. Evaluation of functional capacity afte stroke as a basis for active intervention. Scand. J. Rehabil Med. 1988; 20(3): 111-115.
- Hamilton M. Development of a rating scale for primary depres sive illness. Br. J. Soc. Clin. Psychol. 1967; 6: 278-296.
Supplementary files
